A review of systemic therapy for advanced pancreatic cancer
- PMID: 16258429
A review of systemic therapy for advanced pancreatic cancer
Abstract
Pancreatic cancer remains an important cause of cancer mortality with few long-term survivors. Improvement in the systemic therapy of pancreatic cancer is necessary to treat the frequently encountered metastatic disease. Several new chemotherapeutic agents with modest activity against pancreatic cancer have been identified over the past decade. Gemcitabine is currently the standard treatment for advanced pancreatic cancer. Combination chemotherapy trials incorporating gemcitabine, cisplatin, 5-fluorouracil, oxaliplatin, or irinotecan generally show improved outcomes in objective response rates but with little or no improvement in survival in phase III trials. Novel therapeutic strategies targeting dysregulated molecular pathways in pancreatic cancer cells are currently being explored. Future treatment regimens for pancreatic cancer will probably incorporate conventional cytotoxic drugs and novel targeted agents.
Similar articles
-
[Current aspects of chemotherapy of metastatic pancreatic and biliary tract carcinomas].Praxis (Bern 1994). 2000 Sep 28;89(39):1545-52. Praxis (Bern 1994). 2000. PMID: 11068508 Review. German.
-
The use of chemotherapy in the treatment of advanced gastric and pancreas cancer.Semin Oncol. 1994 Aug;21(4 Suppl 7):58-66. Semin Oncol. 1994. PMID: 8091242 Review.
-
Combinational therapy: new hope for pancreatic cancer?Cancer Lett. 2012 Apr 28;317(2):127-35. doi: 10.1016/j.canlet.2011.11.029. Epub 2011 Dec 2. Cancer Lett. 2012. PMID: 22138436 Review.
-
Efficacy of systemic therapy in advanced pancreatic carcinoma.Acta Oncol. 2006;45(2):136-43. doi: 10.1080/02841860500537861. Acta Oncol. 2006. PMID: 16546858 Review.
-
Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer.Cancer. 2006 Aug 15;107(4):676-85. doi: 10.1002/cncr.22036. Cancer. 2006. PMID: 16847885
Cited by
-
Microarray analysis of nemorosone-induced cytotoxic effects on pancreatic cancer cells reveals activation of the unfolded protein response (UPR).Br J Pharmacol. 2011 Mar;162(5):1045-59. doi: 10.1111/j.1476-5381.2010.01125.x. Br J Pharmacol. 2011. PMID: 21091652 Free PMC article.
-
Gemcitabine induces poly (ADP-ribose) polymerase-1 (PARP-1) degradation through autophagy in pancreatic cancer.PLoS One. 2014 Oct 1;9(10):e109076. doi: 10.1371/journal.pone.0109076. eCollection 2014. PLoS One. 2014. PMID: 25271986 Free PMC article.
-
Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.Anticancer Res. 2009 Dec;29(12):5149-53. Anticancer Res. 2009. PMID: 20044630 Free PMC article. Clinical Trial.
-
Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin.Br J Cancer. 2009 Oct 6;101(7):1155-61. doi: 10.1038/sj.bjc.6605285. Epub 2009 Sep 8. Br J Cancer. 2009. PMID: 19738614 Free PMC article.
-
siRNA directed against survivin enhances pancreatic cancer cell gemcitabine chemosensitivity.Dig Dis Sci. 2009 Jan;54(1):89-96. doi: 10.1007/s10620-008-0329-4. Epub 2008 Jul 2. Dig Dis Sci. 2009. PMID: 18594980
Publication types
MeSH terms
LinkOut - more resources
Medical
Miscellaneous